Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment

British Journal of Pharmacology

Volumn 149, Issue 6, 2006, Pages 740-746

  Slofstra, S H ^a,c   Groot, A P ^a   Maris, N A ^a   Reitsma, P H ^a   Ten Cate, H ^b   Spek, C A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Activated protein C; Inhalation; Lung function; Neutrophil migration; Pulmonary inflammation

Indexed keywords

DROTRECOGIN; ENDOTOXIN; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LUNG ALVEOLUS; LUNG FUNCTION; LUNG LAVAGE; MOUSE; NEBULIZATION; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NEUTROPHILS; PNEUMONIA; PROTEIN C; RESPIRATORY FUNCTION TESTS;

EID: 33750979835     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706915     Document Type: Article

References (38)

1. Adler A, Cieslewicz G, Irvin CG (2004). Unrestrained plethysmography is an unreliable measure of airway responsiveness in BALB/c and C57BL/6 mice. J Appl Physiol 97: 286-292.
2. Bates JH, Irvin CG (2003). Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol 94: 1297-1306.
3. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. (2001). Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709.
4. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B (2003). Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 102: 2093-2098.
5. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC et al. (2003). Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 90: 642-653.
6. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF et al. (2003). Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31: 12-19.
7. Espana F, Gruber A, Heeb MJ, Hanson SR, Harker LA, Griffin JH (1991). In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood 77: 1754-1760.
8. Feistritzer C, Mosheimer BA, Sturn DH, Riewald M, Patsch JR, Wiedermann CJ (2006). Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor. J Immunol 176: 1019-1025.
9. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM et al. (2005). Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 280: 17286-17293.
10. Fujimoto H, Gabazza EC, Hataji O, Yuda H, D'Alessandro-Gabazza CN, Nakano M et al. (2003). Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease. Am J Respir Crit Care Med 167: 1687-1694.
11. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW (1994). Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 153: 3664-3672.
12. Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Sayegh MH et al. (1995). Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 60: 1525-1532.
13. Hooper WC, Phillips DJ, Renshaw MA (2001). Activated protein C induction of MCP-1 in human endothelial cells: a possible role for endothelial cell nitric oxide synthase. Thromb Res 103: 209-219.
14. Johnston RA, Schwartzman IN, Flynt L, Shore SA (2005). Role of interleukin-6 in murine airway responses to ozone. Am J Physiol Lung Cell Mol Physiol 288: L390-L397.
15. Joyce DE, Grinnell BW (2002). Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 30: S288-S293.
16. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE et al. (2004). Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 21: 222-229.
17. Knapp S, Leemans JC, Florquin S, Branger J, Maris NA, Pater J et al. (2003). Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 167: 171-179.
18. Leemans JC, Vervoordeldonk MJ, Florquin S, van Kessel KP, van der Poll T (2002). Differential role of interleukin-6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus. Am J Respir Crit Care Med 165: 1445-1450.
19. Maris NA, van der Sluijs KF, Florquin S, de Vos AF, Pater JM, Jansen HM et al. (2004). Salmeterol, a beta2-receptor agonist, attenuates lipopolysaccharide-induced lung inflammation in mice. Am J Physiol Lung Cell Mol Physiol 286: L1122-L1128.
20. Miller DL, Welty-Wolf K, Carraway MS, Ezban M, Ghio A, Suliman H et al. (2002). Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 26: 650-658.
21. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H et al. (1996). Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 87: 642-647.
22. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H et al. (1997). Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 272: L197-L202.
23. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J et al. (2004). Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104: 3878-3885.
24. Olsen GN, Harris JO, Castle JR, Waldman RH, Karmgard HJ (1975). Alpha-1-antitrypsin content in the serum, alveolar macrophages, and alveolar lavage fluid of smoking and nonsmoking normal subjects. J Clin Invest 55: 427-430.
25. Puneet P, Moochhala S, Bhatia M (2005). Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 288: L3-L15.
26. Schoenmakers SH, Groot AP, Florquin S, Reitsma PH, Spek CA (2004). Blood cell-derived tissue factor influences host response during murine endotoxemia. Blood Cells Mol Dis 32: 325-333.
27. Shimizu S, Gabazza EC, Taguchi O, Yasui H, Taguchi Y, Hayashi T et al. (2003). Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 167: 1416-1426.
28. Shore SA, Schwartzman IN, Le Blanc B, Murthy GG, Doerschuk CM (2001). Tumor necrosis factor receptor 2 contributes to ozone-induced airway hyperresponsiveness in mice. Am J Respir Crit Care Med 164: 602-607.
29. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ (2003). Expression and function of the endothelial protein C receptor in human neutrophils. Blood 102: 1499-1505.
30. Taylor Jr FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE (1987). Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79: 918-925.
31. Uchiba M, Okajima K, Oike Y, Ito Y, Fukudome K, Isobe H et al. (2004). Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ Res 95: 34-41.
32. van der Poll T, Levi M, Nick JA, Abraham E (2005). Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 171: 1125-1128.
33. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF et al. (2005). Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33: 2266-2277.
34. Ware LB, Matthay MA (2000). The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349.
35. Weijer S, Schoenmakers SH, Florquin S, Levi M, Vlasuk GP, Rote WE et al. (2004). Inhibition of the tissue factor/factor VIIa pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice. J Infect Dis 189: 2308-2317.
36. Yasui H, Gabazza EC, Tamaki S, Kobayashi T, Hataji O, Yuda H et al. (2001). Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 163: 1660-1668.
37. Yuda H, Adachi Y, Taguchi O, Gabazza EC, Hataji O, Fujimoto H et al. (2004). Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood 103: 2196-2204.
38. Zeng W, Matter WF, Yan SB, Um SL, Vlahos CJ, Liu L (2004). Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med 32: S302-S308.